Company intelligence / Profile preview

Noven Pharmaceuticals

Miami, Florida, United Statesnoven.com ↗

Ownership: Private
Employees: ~300
Development stage: Commercial

Overview

Noven has received FDA approval for nine products to date. Its commercialized products include the first and only transdermal patches approved for ADHD in children/adolescents and schizophrenia in adults. The company continues to develop new prescription transdermal systems with two developmental products pending regulatory review as of 2024.

Therapeutic areas: PsychiatryWomen's Health
Modalities: Transdermal drug delivery systems (patches)small molecule drugs
Industry: Biotech

Drug pipeline

6 assets

norethindrone acetate transdermal delivery system

5 more assets in the full pipeline.

Request access →

Partnerships

Rhone-Poulenc RorerCiba-GeigyHisamitsu (current collaboration on new technologies/products)

Beyond the preview

Go deeper on Noven Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Noven Pharmaceuticals.

Explore the full profile